Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.

Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA.

Clin Infect Dis. 2012 Apr;54(7):979-83. doi: 10.1093/cid/cir882. Epub 2012 Feb 4.

2.

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.

Pearlman BL.

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29. Review.

PMID:
22647717
3.

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.

Seden K, Back D.

Curr Opin HIV AIDS. 2011 Nov;6(6):514-26. doi: 10.1097/COH.0b013e32834b54dc. Review.

PMID:
22001895
4.

Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.

Laufer NL, Rockstroh JK.

Expert Rev Anti Infect Ther. 2014 Feb;12(2):157-64. doi: 10.1586/14787210.2014.868774. Epub 2013 Dec 18. Review.

PMID:
24350778
5.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
6.

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.

Trembling PM, Tanwar S, Dusheiko GM.

Expert Rev Anti Infect Ther. 2012 Mar;10(3):269-79. doi: 10.1586/eri.12.8. Review.

PMID:
22397560
7.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

8.

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.

Teixeira R, Nascimento Yde A, Crespo D.

Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9. Review.

9.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
10.

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.

Lam JT, Jacob S.

Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500. Review.

PMID:
23230035
11.

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.

Tungol A, Rademacher K, Schafer JA.

J Manag Care Pharm. 2011 Nov;17(9):685-94. Review.

12.

Telaprevir: changing the standard of care of chronic hepatitis C.

Rajani AK, Ravindra BK, Dkhar SA.

J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493. Review.

13.

Future perspectives: towards interferon-free regimens for HCV.

Gane E.

Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Epub 2012 Oct 5. Review.

PMID:
23186654
14.

HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.

Ingiliz P, Rockstroh JK.

Liver Int. 2012 Sep;32(8):1194-9. doi: 10.1111/j.1478-3231.2012.02796.x. Epub 2012 Apr 17. Review.

PMID:
22510096
15.

The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.

Shankar H, Bichoupan K, Dieterich DT.

Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1647-57. doi: 10.1517/17425255.2013.840290. Epub 2013 Oct 1. Review.

PMID:
24079600
16.

Treatment of hepatitis C: a systematic review.

Kohli A, Shaffer A, Sherman A, Kottilil S.

JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085. Review.

PMID:
25117132
17.

Hepatitis C protease and polymerase inhibitors in development.

Liu-Young G, Kozal MJ.

AIDS Patient Care STDS. 2008 Jun;22(6):449-57. doi: 10.1089/apc.2007.0199. Review.

18.

Anemia management in patients with chronic viral hepatitis C.

Hynicka LM, Heil EL.

Ann Pharmacother. 2013 Feb;47(2):228-36. doi: 10.1345/aph.1R513. Epub 2013 Feb 5. Review.

PMID:
23386076
19.

Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.

Fernández-Yunquera A, Rincón D, Salcedo M, Bañares R.

Rev Esp Quimioter. 2013 Sep;26(3):189-92. Review. No abstract available.

20.

Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.

Rodríguez-Torres M.

Curr Opin Infect Dis. 2013 Feb;26(1):50-7. doi: 10.1097/QCO.0b013e32835c2027. Review.

PMID:
23242341

Supplemental Content

Support Center